Abstract
This article submitted to the journal CNS & Neurological Disorders - Drug Targets has been withdrawn upon the request of the author due to the errors and invalid information in the article.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
CNS & Neurological Disorders - Drug Targets
Title:Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients
Volume: 20
Author(s): Mostafa Mohammadi*
Affiliation:
- Islamic Azad University of Central Tehran Branch, Department of Electrical Engineering, Tehran,Iran
Abstract: This article submitted to the journal CNS & Neurological Disorders - Drug Targets has been withdrawn upon the request of the author due to the errors and invalid information in the article.
Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.
The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php
BENTHAM SCIENCE DISCLAIMER:
It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.
Export Options
About this article
Cite this article as:
Mohammadi Mostafa*, Withdrawal Notice: Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients, CNS & Neurological Disorders - Drug Targets 2021; 20 () . https://dx.doi.org/10.2174/1871527320666210129121701
DOI https://dx.doi.org/10.2174/1871527320666210129121701 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Lipid-Activated Nuclear Receptors and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Vaccine Ingredients: Components that Influence Vaccine Efficacy
Mini-Reviews in Medicinal Chemistry Evasion of Host Immunity by Virulent Salmonella: Implications for Vaccine Design
Current Medicinal Chemistry Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) A Review of Recent Patents on the ASICs as a Key Drug Target
Recent Patents on Biotechnology Subject index to volume 1
Current HIV Research Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
Current Medicinal Chemistry HSV Amplicons: Neuro Applications
Current Gene Therapy Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Cornea: Window to Ocular Immunology
Current Immunology Reviews (Discontinued) Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Neural Progenitors and HIV-1- Associated Central Nervous System Disease in Adults and Children
Current HIV Research Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets NS3 Helicases as Drug Targets
Current Chemical Biology